... company's share price growth is attributed to its anti-viral segment, which manufactures drugs for the treatment of HIV/AIDs. This segment contributes more than 80% of the total revenues of the company. In my article, I will analyze the company's ...
http://seekingalpha.com/article/1828292-will-gilead-sciences-be-able-to-continue-its-growth-trajectory?source=feed
http://seekingalpha.com/article/1828292-will-gilead-sciences-be-able-to-continue-its-growth-trajectory?source=feed
No comments:
Post a Comment